Randomized controlled trial of ovarian function suppression plus tamoxifen versus the same endocrine therapy plus chemotherapy: is chemotherapy necessary for premenopausal women with node-positive, endocrine-responsive breast cancer? First results of International Breast Cancer Study Group Trial 11–93
- 1 August 2001
- journal article
- Published by Elsevier in The Breast
- Vol. 10, 130-138
- https://doi.org/10.1016/s0960-9776(16)30022-4
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Combined Tamoxifen and Luteinizing Hormone-Releasing Hormone (LHRH) Agonist Versus LHRH Agonist Alone in Premenopausal Advanced Breast Cancer: A Meta-Analysis of Four Randomized TrialsJournal of Clinical Oncology, 2001
- Systemic adjuvant treatment for premenopausal node-negative breast cancerEuropean Journal Of Cancer, 2000
- Meeting Highlights: International Consensus Panel on the Treatment of Primary Breast CancerJNCI Journal of the National Cancer Institute, 1998
- Tamoxifen for early breast cancer: an overview of the randomised trialsThe Lancet, 1998
- Quality of life assessment in patients receiving adjuvant therapy for breast cancer: The IBCSG approachAnnals of Oncology, 1997
- Timing of radiotherapy and chemotherapy following breast-conserving surgery for patients with node-positive breast cancerInternational Journal of Radiation Oncology*Biology*Physics, 1996
- Impact of adjuvant therapy on quality of life in women with node-positive operable breast cancerThe Lancet, 1996
- Regression Models and Life-TablesJournal of the Royal Statistical Society Series B: Statistical Methodology, 1972
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958